Drug intelligence / Profile preview

LEO 27989

Development stage: Phase 1
Lead developer: LEO Pharma
Modality: Small Molecules
Administration: Topical

Overview

LEO 27989 is a small molecule drug developed by LEO Pharma as a topical ointment for the treatment of plaque psoriasis and psoriasis vulgaris. Its precise mechanism of action has not been defined or disclosed in public sources. The drug was evaluated in phase 1 clinical trials to assess its anti-psoriatic effects, both alone and in combination with calcipotriol. As of the latest available updates, no further development beyond phase 1 has been reported[1][2][3].

Beyond the preview

Go deeper on LEO 27989.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LEO 27989.

Explore the full profile